Eye-care AI firm Bigway Medical raises $4.48M Series B extension
What's the deal? Suzhou Bigway Medical TechnologyDealroom has a profile for this one. Try Dealroom → has raised a US$4.13M (roughly $4.48 million) Series B extension, led by Ji'an Lanwan Venture Capital with participation from Jiangxi Modern Equity Investment. The company develops ophthalmic AI products spanning smart imaging devices, AI-assisted diagnostic software, and a data-management platform.
Why now? The round follows a US$4.13M raise in 2024 and arrives as China pushes AI into clinical care. In November 2025, the National Health Commission and four other bodies issued guidance targeting near-universal AI-assisted diagnosis at primary-care level by 2030.
What's the endgame? Bigway is scaling a multimodal, full-process ophthalmic system that links screening, diagnosis, treatment, and follow-up. In August 2026, a system it supplied — integrating six devices and a management platform — went into clinical use at Sichuan Provincial People's Hospital, with plans to connect over 10 lead hospitals, 100-plus city hospitals, and 1,000-plus grassroots clinics.
By the numbers: Bigway's products are now in more than 1,000 medical institutions, serving over one million people and covering more than two million eyes. Its OCT diagnostic software MIAS-US$2.52 Class III device approval from the National Medical Products Administration in October 2025, which the company describes as the world's first such clearance for a medical OCT AI system.
The firm holds five Class II hardware registrations, one Class II software registration, and one Class III AI registration. Clinical trial data put MIAS-3000's single-eye sensitivity at 95.5%, with 98.04% sensitivity for wet age-related macular degeneration.
Where the money goes: The proceeds will fund rollout of the multimodal system and overseas expansion. Bigway began international work in 2024 and has since built ties across Europe, the Americas, Asia, and Africa, signing agency agreements in markets including the US, UK, Italy, India, Brazil, and Zambia.
What could go wrong? Expanding abroad means navigating varied regulatory regimes, hospital procurement rules, and service systems that differ sharply from China's. Early traction in ultra-widefield cameras and OCT devices will need to convert into sustained orders.
What they're saying: Investor Tian Junfeng of Ji'an Lanwan said MIAS-3000's status as the "world's first" Class III medical OCT AI clearance reflects Bigway's research depth and competitiveness in the field.
The signal: China's eye-care AI market is shifting from single-image analysis toward device coordination and full-process management, pulled forward by new state policy. Bigway's extension round shows how firms with combined hardware, software, and data platforms are now racing to prove scale — at home and abroad.
Read more: sohu.com
Image credit: Generated with Gemini
